Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,D-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy

1997-05-12

Additional Metadata
Keywords	[DOTA0,D-Phe1,Tyr3]octreotide, Biodistribution, Indium-111, Receptor binding, Yttrium-90
Persistent URL	doi.org/10.1007/s002590050064, hdl.handle.net/1765/64878
Journal	European Journal of Nuclear Medicine
Organisation	Department of Internal Medicine
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	de Jong, M., Bakker, W., Krenning, E., Breeman, W., van der Pluijm, M., Bernard, B., Visser, T., Jermann, E., Béhé, M., Powell, P.& Mäcke, H. (1997). Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,D-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. European Journal of Nuclear Medicine, 24(4), 368–371.https://doi.org/10.1007/s002590050064

Publication